( DURHAM N.C.--(BUSINESS WIRE)--Jun 12 ...)Inspire Announces Presentations at Two European Scientific,Conferences,Health

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI) being held June 9-13, 2007 in Goteborg, Sweden and at the 30th European Cystic Fibrosis Society (ECFS) Conference being held June 13-16, 2007 in Belek, Turkey.

The EAACI Congress includes two presentations with clinical data on bilastine, a compound in development by FAES Farma, S.A. for the treatment of allergic rhinitis, which is partnered with Inspire in the United States and Canada, and one presentation with scientific data on epinastine, bilastine and other antihistamines for treating allergies. -0-

-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily

   Bilastine with Cetirizine and Placebo for the Treatment of Seasonal

   Allergic Rhinitis

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Treatment with Bilastine Improves Symptoms in Patients with

   Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy

   and Safety of Once Daily Bilastine with Desloratadine and Placebo

   for the Treatment of Seasonal Allergic Rhinitis)

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Evaluation of Muscarinic Receptor Antagonism by Antihistamines

   Poster and brief oral presentation on Tuesday, June 12, 2007

The ECFS Conference includes two presentations with clinical data on denufosol, a compound in development by Inspire for the treatment of cystic fibrosis. -0-

-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists -

   Evidence of High Lung Delivery and Minimal Systemic Exposure

   Poster presentation on Thursday and Friday, June 14-15, 2007 and

   oral presentation on Thursday, June 14, 2007


-- Reactive Airway Disease and
'"/>




Page: 1 2 3 
Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine
Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in
Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease